Loading…
Based on limited metadata, this FDA Warning Letter issued to Glenmark Pharmaceuticals Limited on October 3, 2019, addresses compliance concerns related to drug manufacturing or operations. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The letter falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided.